Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

PURPOSE: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaxley, William John, McBean, Rhiannon, Wong, David, Grimes, David, Vasey, Paul, Frydenberg, Mark, Yaxley, John William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566790/
https://www.ncbi.nlm.nih.gov/pubmed/34729965
http://dx.doi.org/10.4111/icu.20210097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566790/
https://www.ncbi.nlm.nih.gov/pubmed/34729965
http://dx.doi.org/10.4111/icu.20210097

Ejemplares similares